Cargando…

Direct costs of treating men with prostate cancer with High Intensity Focused Ultrasound (*)

OBJECTIVE: To analyze the direct costs of materials, medicines/solutions and healthcare professionals required to treat men with prostate cancer using High Intensity Focused Ultrasound. METHOD: Quantitative, exploratory-descriptive research, single case study type. Data were collected from electroni...

Descripción completa

Detalles Bibliográficos
Autores principales: da Silva, Pâmela Adalgisa Lopes, Lima, Antônio Fernandes Costa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Universidade de São Paulo, Escola de Enfermagem 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680442/
https://www.ncbi.nlm.nih.gov/pubmed/38009909
http://dx.doi.org/10.1590/1980-220X-REEUSP-2023-0132en
Descripción
Sumario:OBJECTIVE: To analyze the direct costs of materials, medicines/solutions and healthcare professionals required to treat men with prostate cancer using High Intensity Focused Ultrasound. METHOD: Quantitative, exploratory-descriptive research, single case study type. Data were collected from electronic medical records/printed documentation from the Operating Room of a public teaching and research hospital. Health professionals estimated the respective time spent on activities in the following stages: “Before anesthetic induction”, “Before performing thermal ablation”, “During thermal ablation” and “After performing thermal ablation”. Costs were calculated by multiplying the (estimated) time spent by the unit cost of direct labor, adding to the measured cost of materials, medicines/solutions. RESULTS: The measured costs with materials corresponded to US$851.58 (SD = 2.17), with medicines/solutions to US$72.13 (SD = 25.84), and estimated personnel costs to US$196.03, totaling US$1119.74/procedure. CONCLUSION: The economic results obtained may support hospital managers in the decision-making process regarding the adoption of the High Intensity Focused Ultrasound for the treatment of prostate cancer.